Prostatitis currently exhibits a growing pipeline with 11 drug candidates, According to P&S Intelligence
The study analyzed that the prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development. Prostatitis is an infection or inflammation of the prostate gland that can lead to various syndromes with varying clinical features. The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The National Institutes of Health (NIH) has recognized and defined a classification system for prostatitis in 1999.
Access Report Summary with Detailed TOC on "Prostatitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/prostatitis-therapeutics-pipeline
Insights on pipeline segments
According to the research findings, one drug candidate has entered the Phase III stage of development in prostatitis therapeutics pipeline.
Drug Candidates with Oral Route of Administration tend to Increase Patient Compliance
The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini Acraf SpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase.
Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.
Prostatitis Therapeutics Pipeline Analysis